Degroof Petercam - Oncodesign Precision Medicine (ALOPM) (Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

Report

Degroof Petercam

David Seynnaeve, PhD

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

*OPM reported the final results of its Ph1 study with RIPK2 inhibitor ‘OPM-101'. Ph1b/2a expected to launch early 2025.*While results look highly encouraging, with strong safety data and no cardiac toxicity, we await clarity on the Ph1b/2a trial protocol and pursued indication.*Our rNPV-based valuation takes into account estimates related to OPM-101 and OPM-201 and does not factor in the potential dilutive impact of any future capital raises. Discovery/preclinical-stage programs are considered upside for the time being. We recommend to Buy the stock considering the attractive 66% upside and in light of the OPM-201 Ph1 results for Parkinson's disease (expected in

23/10/2024 1 EN

Underlying

Oncodesign Precision Medicine

See profile

Provider

Degroof Petercam

We are an investment house with Belgian roots founded on more than 150 years of trust.

As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.

See profile

Analysts

David Seynnaeve, PhD

Other Reports on these Companies

Degroof Petercam

(Sponsored) Oncodesign Precision Medicine - H1 update: clarity around OPM-101 strategy expected towards year-end

*Recently, OPM provided an H1 update, most notably confirming Ph1b/2a commencement with OPM-101 end of 2024/early 2025. *Furthermore, the company indicated that the Ph1 for Parkinson's disease with OPM-201 is wrapping up soon - we expect results in H1 2025 (10% TP upside) – with Servier preparing for a follow-up Ph1b/2a study which is likely to trigger a milestone payment and consequently strengthen OPM's cash position (which stood at close to EUR 10m end of June).*Based on an updated net cash position and rolling forward our DCF 6 months, we arrive at a TP of EUR 2.1 (vs. EUR 1.9-2....

September 27, 2024 September 27, 2024 1 EN

Degroof Petercam

(Sponsored) Oncodesign Precision Medicine - OPM-101 Ph1 data prompt further clinical development

Yesterday, OPM announced successful completion of its Ph1 study with healthy volunteers for its RIPK2 inhibitor ‘OPM-101'. Data indicates safety, rapid onset of action, and strong/sustained target engagement.Ph1b/2a expected to commence by year-end with indication to be determined (prioritization of immune checkpoint inhibitor-induced colitis not reiterated) and study design to be finalized. Hence, we are somewhat left in the dark regarding next steps and therefore look forward to an update regarding the asset's further development.We consider the data to be promising, especially wit...

July 18, 2024 July 18, 2024 1 EN

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

Whitestone's NAV almost tripled in size over H1 from EUR 34.4m to EUR 99.7m at June 30.The majority of the immense growth is thanks to two capital raises with in total EUR 59.7m raised.The remainder of the growth comes from the solid performance in the portfolio (+EUR 6m).The company still has more than EUR 20m in cash available to deploy, even after its most recent investment in Lambda X Ophtalmics.We estimate today's NAV at EUR 14.5 p/s implying a discount of 16.5%. Our TP moves to EUR 13.4 (was EUR 13.9) and we reiterate our Hold rating.

October 28, 2024 October 28, 2024 1 EN

Luuk Van Beek

Luuk Van Beek

(Sponsored) Cabka - Encouraging sales trend in Q3

Q3-24 sales increased 8% to EUR 42.4m, showing an encouraging sequential trendManagement reiterates its guidance for EUR 180-185m in revenues and a 13-15% EBITDA margin in 2024We will fine-tune our estimates and reiterate our Buy and EUR 4.60 TP

October 21, 2024 October 21, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

(Sponsored) Oncodesign Precision Medicine - Final Ph1 results of RIPK2 inhibitor OPM-101 paving the way for Ph1b/2a launch

(Sponsored) Oncodesign Precision Medicine - H1 update: clarity around OPM-101 strategy expected towards year-end

(Sponsored) Oncodesign Precision Medicine - OPM-101 Ph1 data prompt further clinical development

(Sponsored) Whitestone Group - H1-24: Very active first half and ready to invest

(Sponsored) Cabka - Encouraging sales trend in Q3

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe